Carbapenem-Resistant Enterobacteriaceae - 14/12/17

Doi : 10.1016/j.cll.2017.01.005

Alina Iovleva, MD ^a, Yohei Doi, MD, PhD ^b,^⁎
^a Division of Infectious Diseases, University of Pittsburgh School of Medicine, Falk Medical Building, Suite 3A, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
^b Division of Infectious Diseases, University of Pittsburgh School of Medicine, S829 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA

^∗Corresponding author.

Résumé

Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.

Le texte complet de cet article est disponible en PDF.

Keywords : Carbapenemase, KPC, Rapid diagnosis

Plan

	Funding: The effort of Y. Doi was supported by research grants from the National Institutes of Health (R01AI104895, R21AI123747).
	Transparency Declarations: Y. Doi has served on advisory boards for Meiji, Achaogen, Allergan, Curetis, and has received research funding from The Medicines Company for a study unrelated to this work. A. Iovleva declares no conflicts of interest.